Workflow
MiNK Therapeutics Reports Fourth Quarter & Full Year 2024 Results and Highlights Business Progress
MiNK TherapeuticsMiNK Therapeutics(US:INKT) Newsfilter·2025-03-18 19:30

NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ:INKT), a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf invariant natural killer T (iNKT) cell therapies, today announced its financial results for the fourth quarter and full year 2024, highlighting significant business progress and clinical advancements. The company will host a conference call and webcast at 8:30 a.m. ET. "Throughout 2024, MiNK advanced its mission to bring off-th ...